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Patients at high risk for Venous Thrombosis(VT) following knee arthroscopy could potentially 31 
benefit from thromboprophylaxis. We explored the predictive values of environmental, 32 
genetic risk factors and levels of coagulation markers to integrate these into a prediction 33 
model. Using a population based case-control study into the aetiology of VT we developed a 34 
Complete (all variables), Screening (easy to use in clinical practice) and Clinical (only 35 
environmental risk factors) model. The Clinical model was transformed into the L-36 
TRiP(ascopy) score. Model validation was performed both internally and externally in 37 
another case-control study. 4943 cases and 6294 controls were maintained in the analyses, 38 
107 cases and 26 controls had undergone knee arthroscopy. Twelve predictor variables (8 39 
environmental, 3 haemorheological and 1 genetic) were selected from 52 candidates and 40 
incorporated into the Complete model (Area Under the Curve(AUC) of 0.81, 95%CI 0.76–41 
0.86). The Screening model  (9 predictors:  environmental factors plus FVIII activity) reached 42 
an AUC of 0.76 (95%CI 0.64–0.88) and the Clinical (and corresponding L-TRiP(ascopy) model 43 
an AUC of 0.72 (95%CI 0.60 – 0.83). In the internal and external validation, the Complete 44 
model reached an AUC of 0.78 (95%CI 0.52–0.98) and 0.75 (95%CI 0.42-1.00), respectively, 45 
while the other models performed slightly less well.  46 





Introduction  50 
In general, orthopaedic surgery is associated with a high risk of venous thrombosis (VT), the 51 
composite of deep vein thrombosis (DVT) and pulmonary embolism (PE).(1) This can be 52 
understood when we consider the long duration of surgery, the extensive tissue damage 53 
during hip or knee replacement and the associated immobilization. For general knee 54 
arthroscopy this is different: hardly any tissue damage occurs and the duration of the 55 
procedure is short (15-20 min). However, the risk of VT following arthroscopy of the knee is 56 
not negligible, with symptomatic incidence rates varying around 1%.(2-6) Knee arthroscopy 57 
is the most commonly performed orthopaedic procedure with worldwide 4 million 58 
arthroscopies carried out yearly.(7) Therefore, this will lead to high absolute numbers of, 59 
theoretically preventable, VT cases (40 000 VTs annually assuming a risk of 1%). In addition, 60 
numerous fatal cases after surgery have been described(8, 9), as can be expected based on a 61 
30-day VT fatality rate of 3.0%.(10) Hence, on estimation 1 200 patients die yearly within 30 62 
days after knee arthroscopy worldwide. Moreover, long term complications such as post-63 
thrombotic syndrome affect about 40% of thrombosis patients.(11) Therefore the impact of 64 
VT is considerable, even in this generally young and healthy patient population.  65 
Several studies have been performed to obtain more insight in the development of VT after 66 
arthroscopic knee surgery. Recently, we showed in the POT-KAST trial, a large Randomized 67 
Controlled Trial (1 451 patients) comparing Low Molecular Weight Heparin with no 68 
treatment, that there is no effectiveness for thromboprophylaxis following knee 69 
arthroscopic surgery, as the risk of VT was equal (~ 0.6%) in the treated and untreated 70 
group.(12)  71 
Multiple high risk groups appear to exist: It was recently described that hospital admission 72 
before surgery was predictive of thrombosis (Hazard Ratio 14.1, 95% CI: 5.3–37.6).(3) 73 
Another study showed that patients undergoing anterior cruciate ligament (ACL) 74 
reconstruction had a higher VT risk compared with patients undergoing less invasive 75 
arthroscopic procedures.(13) Other risk factors, such as a history of malignancy(2), a history 76 
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of VT(14),  use oral contraceptives, being overweight or having a genetic predisposition 77 
(Factor V Leiden, non-O blood type, prothrombin 20210A mutation) have also been 78 
identified to elevate postoperative risk.(2, 15) Hence, it should theoretically be possible to 79 
distinguish between high or low risk of VT after knee arthroscopy by combining all 80 
information into one prediction model, instead of measuring single risk factor associations. If 81 
these groups can be targeted, the considerable morbidity and mortality due to VT after this 82 
procedure may yet be preventable. 83 
The aim of this study was to investigate the combined predictive value of environmental and 84 
genetic risk factors, biomarkers and levels of coagulation markers on the development of VT 85 
in knee arthroscopy patients. We aimed to develop a prediction model to assist clinicians to 86 





Study design 90 
For model development, data from a large population based case-control study, the Multiple 91 
Environmental and Genetic Assessment of risk factors for venous thrombosis (MEGA study) 92 
were used. Details of this study have been published previously.(16) In short, between 1999 93 
and 2004, all consecutive patients aged 18 to 70 years with a first deep vein thrombosis, 94 
pulmonary embolism or both were recruited from six anticoagulation clinics in the 95 
Netherlands (n=4 956). The control-group (n=6 297) consisted of partners of participating 96 
patients and of other controls who were frequency matched with respect to sex and age and 97 
identified using a random digit dialling method. Approval for this study was obtained from 98 
the Medical Ethics Committee of the Leiden University Medical Center and all participants 99 
provided written informed consent.  100 
 101 
Data collection and laboratory analysis 102 
All participants completed a questionnaire, including potential risk factors for VT such as 103 
orthopaedic surgery, current use of medication and co-morbidity in the year before the 104 
venous thrombotic event.  105 
 A blood sample was collected approximately three months after discontinuation of 106 
oral anticoagulant therapy for patients and controls included from the start of the study 107 
until May 31, 2002. Detailed information on laboratory analyses from coagulation and 108 
hemorheologic and other markers can be found in Supplement 1. In patients who were still 109 
on anticoagulant therapy one year after the event, blood was drawn during treatment. After 110 
June 1, 2002 and for participants who were unable to visit the clinic, DNA was collected by 111 
means of buccal swabs sent by mail. Factor V Leiden (F5, rs6025), prothrombin G20210A (F2, 112 





Model Derivation 116 
The prediction model was developed using the data from the MEGA study population. 117 
Subjects with multiple orthopaedic surgeries or other operations in combination with a knee 118 
arthroscopy were excluded from analyses. To incorporate age and sex as predictor variables 119 
(because controls were frequency matched on age and sex) we weighted control subjects 120 
(for age and sex) to the age and sex distribution of the Dutch population in 2001 (Statistics 121 
Netherlands). Missing values were imputed (we imputed 5 datasets by multiple imputation 122 
and results were pooled according to Rubin’s rules). Vitamin K dependent coagulation 123 
factors from patients who were still on anticoagulation treatment during blood collection 124 
were set as missing values and imputed as well. Supplement 2 provides detailed information 125 
on missing data for risk factors incorporated in the prediction model.  126 
 127 
We aimed to develop three models; a Complete model (all variables and highest 128 
discriminative ability), a Screening model (including a minimum number of all types of 129 
predictors with maximum discriminative performance to improve clinical usefulness) and a 130 
Clinical model (only environmental risk factors). Development of all models was based on a 131 
method we described in a previous study, using a multivariate logistic regression 132 
approach.(17) In short, candidate predictors were identified in the whole MEGA study 133 
population (n=11 237) (step 1 and 2) (Fig 1). Candidate predictors (already derived from our 134 
previous study) were entered in the Complete prediction model by hand, and a univariate 135 
logistic regression was conducted for all candidate predictors in the entire MEGA group  136 
(step 3). We started fitting our Complete model with the strongest predictor (based on 137 
highest Area Under the Curve [AUC] in the arthroscopy subgroup) (n=133). Further predictor 138 
selection was based on the variable that resulted in the strongest increase in AUC, in the 139 
knee arthroscopy subgroup (step 4) (addition of predictors was stopped when AUC increase 140 
was less than 0.01 points). Age and sex were forced in all models based on clinical 141 
importance. For calculating the AUC, a Receiver Operating Characteristic (ROC) was 142 
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constructed. Model overfitting was prevented by conducting a ROC analysis in the 143 
arthroscopy subgroup only (using the beta coefficient derived from the logistic regression 144 
model calculated in the entire MEGA study population [n=11 237]) instead of conducting a 145 
regression in the small arthroscopy subgroup. Next to a Complete model, a Screening model 146 
was developed in a similar way (step 5). Finally, we developed a Clinical model using 147 
environmental risk factors only (step 6).  148 
 149 
Risk Score 150 
We developed a Risk Score, the Leiden-Thrombosis Risk Prediction(arthroscopy) score, [L-151 
TRiP(ascopy) score] for VT risk following knee arthroscopy that was based on the beta 152 
coefficients for predictor variables in the Clinical model (using the following rule: if Beta was 153 
>0.25 and ≤0.75, this yielded 1 point, for; Beta>0.75 and ≤1.25=2 points; Beta>1.25 and 154 
≤1.75=3 points; Beta>1.75 and ≤2.25=4 points; Beta>2.25 and ≤2.75=5 points; Beta>2.75=6 155 
points). The L-TRiP(ascopy) score was the sum of these points. Assuming two overall 156 
prevalences of either 0.5% or 1.5% for VT in patients who undergo knee arthroscopy, we 157 
calculated sensitivity, specificity, positive predictive value, negative predictive value, positive 158 
likelihood ratio and the negative likelihood ratio for different cut off points of the L-159 
TRiP(ascopy) score.  160 
 161 
Model validation 162 
A bootstrapping procedure was performed to internally validate our results. Using the 163 
imputed dataset, we resampled our arthroscopy subgroup (1000 replications with 164 
replacement), after which all models were validated in this new population. In addition, THE 165 
VTE case-control study into the aetiology of VTE, which contains 784 cases and 523 controls 166 
(Leiden/Cambridge) was used for external validation of the L-TRiP(ascopy) score. Details of 167 
this study have been published previously.(18) For each subject in THE VTE study, prognostic 168 
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scores were calculated using regression coefficients from the prediction models derived 169 
from the MEGA study. 170 
All analyses were performed in IBM SPSS Statistics for Windows, Version 20.0. Armonk, NY: 171 




Study population 174 
4 943 cases and 6 294 controls were maintained in the analyses after exclusion of 13 175 
participants who underwent multiple orthopaedic operations after the arthroscopy. Among 176 
all cases 2 881 (58%) had a DVT, 1618 (33%) a PE and 444 (9%) both. 107 cases and 26 177 
controls had undergone knee arthroscopy within one year before thrombosis or index date, 178 
respectively (of whom most patients (~75%) within 3-months(19)). Thirteen of them (10%) 179 
underwent ligament reconstruction from the anterior cruciate ligament and/or posterior 180 
cruciate ligament. Compared with the complete MEGA study population, subjects who 181 
underwent knee arthroscopy were slightly younger (mean 44.6 years vs 47.7 years), and 182 
more often male (58% vs 46%).  183 
 184 
Model derivation 185 
52 candidate predictors were identified in the MEGA study population (Table 1). Strong 186 
predictors in both the total MEGA study population and arthroscopy subgroup were: family 187 
history of venous thrombosis, current use of oral contraceptives and having been bedridden 188 
within the past 3 months. Persons who underwent knee arthroscopy without ligament 189 
reconstruction had a 5-fold increased risk of developing VT, odds ratio (OR) 5.1, 95% 190 
confidence interval (95%CI 3.3 – 8.0), while those who had cruciate ligament reconstruction 191 
had an 18-fold increased risk (OR 17.5 [95%CI 2.3 – 134.8]), compared with subjects who did 192 









  200 
Complete model 201 
Twelve predictor variables (8 environmental risk factors, 3 hemorheologic factors and 1 202 
genetic marker) were incorporated into the Complete prediction model. Risk factors 203 
included in the model were: age, sex, Von Willebrand Factor (vWF) activity, family history of 204 
VT, Factor V Leiden mutation (FV Leiden), having been bedridden within the past 3 months, 205 
current use of oral contraceptives, (type) of knee arthroscopy, Factor VIII (FVIII) activity, 206 
presence of varicose veins, monocyte percentage and having congestive heart failure. This 207 
combination of risk factors resulted in an AUC of 0.81 (95%CI 0.70 – 0.93) (Table 2). Fig 2 208 
shows the AUC values of our Complete model after step-wise addition of these predictor  209 
variables. 210 
 211 
Screening model  212 
Our Screening model consisted of nine predictors (all environmental risk factors of the 213 
Complete model plus FVIII activity) and reached an AUC of 0.76 (95%CI 0.64 – 0.88). 214 
Although vWF increased model performance more than FVIII (AUC increase of 0.02), FVIII 215 
was chosen over vWF as FVIII activity can be measured more easily in most clinics.  216 
 217 
Clinical Model and L-TRiP(ascopy) score 218 
The Clinical model resulted in an AUC of 0.72 (95%CI 0.60 – 0.83) and consisted of all eight 219 
environmental risk factors that were also included in the Complete and Screening model. 220 
The L-TRiP(ascopy) score (Table 3) derived from this model resulted in an AUC of 0.73 (95%CI 221 
0.63 – 0.84). Table 4 gives an overview of discriminative values for all cut-off points from the 222 
L-TRiP(ascopy) score. For example, a cut-off value of 7 results in a sensitivity and specificity 223 
of 77.8% and 40.2% respectively, to identify patients at high risk of developing VT. Figure 3 224 




Internal and external validation  227 
In the bootstrapped population the Complete and Screening models performed almost as 228 
good as in the derivation dataset, whereas the L-TRiP(ascopy) score and Clinical model 229 
performed somewhat less well (Table 2). The L-TRiP(ascopy) score resulted in an AUC of 0.67 230 
(95%CI 0.54 – 0.80) while the complete model reached an AUC of 0.78 (95%CI 0.67-0.89). 231 
 232 
The population study used for external validation consisted of 784 cases and 523 controls 233 
that were included in THE VTE study. 59% of all cases had DVT and 41% had PE with or 234 
without DVT. 30 cases and 3 controls had undergone knee arthroscopy within one year 235 
before VT. The Complete model resulted in an AUC of 0.75 (95%CI 0.52 – 0.98) and the 236 
Screening model yielded an AUC of 0.73 (95%CI 0.49 – 0.96). For our Clinical model and L-237 
TRiP(ascopy) score the AUCs were 0.78 (95%CI 0.48 – 1.00) and 0.77 (95%CI 0.43 – 1.00), 238 
respectively. Table 2 gives an overview of the predictive values for all models in both 239 






Summary of key findings 244 
Patients who undergo knee arthroscopy have an increased risk of developing VT. We 245 
developed and validated a prediction model to identify patients at high risk for this 246 
complication. Because of the bleeding risk during thromboprophylactic therapy and the low 247 
risk of VT, risk stratification is likely to be beneficial, which can be achieved by using the L-248 
TRiP(ascopy) score. Our results indicate that biomarker determination leads to more 249 
accurate risk prediction than limiting to clinical variables. However, for clinical practice a 250 
clinical model without additional biomarker testing can be preferred until larger validation 251 
studies show a strong added value of biomarker testing. 252 
 253 
Risk factors for VT in knee arthroscopy patients  254 
A recent cohort study of 12 595 patients found a symptomatic VT incidence of 0.34% (95% CI 255 
0.25 – 0.46) at 4 weeks. Risk factors for VT were: a history of malignancy, a history of VT and 256 
the presence of two or more risk factors according to Delis (age>65, BMI>30, smoking, use of 257 
oral contraceptives or hormonal replacement therapy, chronic venous insufficiency, history 258 
of VT).(2) A similar incidence of 0.46% (95% CI 0.43 - 0.49) was found by Bohensky and 259 
colleagues, in a cohort study with 180 717 arthroscopies.(20) In this study only chronic 260 
kidney disease was found to be a clear risk factor for the development of VT while patients 261 
with cancer, peripheral vascular disease, chronic heart failure, cerebrovascular event, 262 
myocardial infarction, chronic lung disease, hemiplegia or diabetes were not at increased 263 
risk after arthroscopy. A study from New York reported on predictors of pulmonary 264 
embolism following a knee arthroscopy among 418 323 operations. The 30-day incidence 265 
was 2.8 per 10 000 knee arthroscopies and risk factors for the development of VTE were 266 
age>30, female sex, history of cancer and an operating time over 90 minutes. Type of 267 
surgery or presence of comorbidity was not associated with VT.(21) Another observational 268 
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study with 4 833 patients undergoing arthroscopic surgery showed that only older age and 269 
hospitalization in the preceding 3 months were predictors of VT.(3) 270 
All these studies had an observational design, and information bias cannot be ruled out: 271 
Data on comorbidities were collected using large hospital or nationwide databases. Data 272 
collection or reporting on putative risk factors may have been more rigorous for patients 273 
with VT than for those without, which could be an explanation for the contradicting results 274 
on different risk factors as shown by several of these studies. Also, logistic regression 275 
analyses in these studies were often underpowered because of the low incidence rate and 276 
scarce distribution of risk factors. In our study cases and controls were asked to complete 277 
questionnaires about their health one year prior to the VT date or a random control date, 278 
respectively (this active approach reduced the risk of bias). The number of cases in our study 279 
used for the regression analysis (n=4 943) is much more than the total number of events in 280 
previous studies. Therefore the predictive values of various risk factors, derived from all 281 
patients, are more accurate in our study. Furthermore, prediction of high risk patients in this 282 
population with a low incidence of VT is more valuable than identifying individual risk 283 
factors. Our goal was therefore not to estimate associations of single risk factors, but to 284 
combine all information for optimal individual risk stratification. 285 
 286 
Specific aspects of the patient population that undergoes knee arthroscopy may also have 287 
contributed to the conflicting results that have been reported. In the study from New York, 288 
92.3% of all patients had a Charlson/Deyo comorbidity score of 0, meaning that they had no 289 
history of myocardial infarction, congestive heart failure, peripheral vascular disease, 290 
cerebrovascular disease, dementia, chronic pulmonary disease, rheumatologic disease, 291 
peptic ulcer disease, liver disease, diabetes mellitus, (para)plegia, renal disease or AIDS.(21) 292 
Similar patient characteristics were reported by Jameson, where 90% had a Charlson/Deyo 293 
score of 0 and the mean age was 45.9 years.(22) These studies illustrate that patients 294 
undergoing knee arthroscopy are in general young and healthy with only very few 295 
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comorbidities. Consequently, while comorbidity is associated with VT risk in other situations, 296 
there is limited contribution of environmental risk factors to risk stratification in the 297 
arthroscopic population. A similar problem exists when using other prediction scores for 298 
VTE, for instance the Caprini score(23). According to this score, patients who undergo 299 
arthroscopic surgery score 2 points, indicating a moderate risk for VTE. Consequently, all 300 
patients who undergo arthroscopy receive thromboprophylaxis and a further discrimination 301 
between low- and high-risk patients within a surgical subgroup (such as knee arthroscopy), 302 
cannot be made.  303 
 304 
Given the young and healthy population with few environmental risk factors, we 305 
investigated the additional predictive value of biomarkers (that are easy to determine in a 306 
clinical setting). To our knowledge, this has not been done in knee arthroscopy patients for 307 
the development of VT to date. We found that addition of FVIII concentration (FVIII;C), vWF 308 
activity, Factor V Leiden mutation (FV Leiden) and monocyte percentage to our model 309 
increased the predictive value. However, to improve clinical usefulness we attempted to 310 
minimalize the number of biomarkers. Out of the biomarkers that were associated we chose 311 
to incorporate FVIII in the Screening model for practical reasons. The Screening model 312 
performed slightly better than the L-TRiP(ascopy) score, (AUC difference in derivation study 313 
0.03 points, and 0.07 point in internal validation). Our external validation study was not 314 
powered sufficiently to clearly show a beneficial effect of FVIII, and all models performed 315 
roughly similarly (AUC range 0.75-0.78). Therefore we finally opted to convert the Clinical 316 
model in the L-TRiP(ascopy) score, rather than the Screening model as the predictive value 317 
of adding a biomarker did not outweigh the hassle of measuring factor VIII (in terms of costs, 318 
and  logistics in routine clinical care). However, it should be kept in mind that due to less 319 
discriminatory power, there will be overtreatment of controls (Table 4).  320 
 321 
Limitations of the study 322 
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Our study lacked information on thromboprophylaxis therapy after knee arthroscopy for all 323 
individuals. However, in a survey study in the Netherlands which was performed during the 324 
same period as the inclusion period of our case-control study, 71% of all orthopaedic 325 
surgeons stated that they used a low-molecular-weight-heparin (LMWH) for prophylactic 326 
therapy in patients undergoing a knee arthroscopy in most cases. 91% of these surgeons 327 
only used a single-dose of LMWH.(24) This could have affected the actual risk in our patient 328 
population. Nevertheless, the therapeutic value of a single dose of LMWH is not known and 329 
probably limited. In addition, as we recently showed that thromboprophylaxis is not 330 
effective for VTE prevention following knee arthroscopy(12), the effect of prophylaxis on VTE 331 
development (and thus on model development) is negligible.  Furthermore, the L-332 
TRiP(ascopy) model was developed by identifying candidate predictors using all cases and 333 
controls from the MEGA study. Beta-coefficients and risk points in the final risk score were 334 
based on many patients, thereby preventing over-fitting. An additional internal validation 335 
showed similar performance statistics, indicating the robustness of model performance. 336 
Also, our validation cohort did not include sufficient numbers of patients (especially control 337 
subjects) with knee arthroscopy to obtain precise results. Validation results were therefore 338 
not very precise, however, all models performed promisingly and were in line with the 339 
derivation results. To account for this problem, an internal validation was performed to 340 
confirm our findings, which showed similar results. However, a larger validation study (and 341 
perhaps a cost-effectiveness study) is still needed to confirm our results and to determine if 342 
biomarkers are needed to improve risk prediction following knee arthroscopy.  343 
 344 
Clinical implications 345 
To date, there is no consensus on thromboprophylactic therapy for patients who underwent 346 
knee arthroscopy. However, we recently published a large randomized controlled trial (POT-347 
KAST trial) that showed a lack of effectiveness for thromboprophylaxis for 8 days after knee 348 
arthroscopy (1451 patients).(12) In this trial, still 0.6% of patients developed a thrombotic 349 
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event and these patients had several additional risk factors for VT. Our L-TRiP(ascopy) score 350 
can be a helpful tool to guide doctors in their decision on anticoagulant treatment for those 351 
patients at high risk for VT. Since we showed that a prophylactic dose of anticoagulant 352 
therapy does not prevent VT, other treatment regimens (such as a longer therapy duration 353 
or higher dosage) might be effective in those patients with an extremely high risk, but 354 
should also be restricted to this group, considering the high bleeding risk, which is currently 355 
about 0.5% major and clinically relevant non-major bleeding(12). Increasing the duration 356 
and dosage of thromboprophylaxis will likely lead to a further increased bleeding risk. Since 357 
bleeding risk is already nearing VTE risk, it is crucial to identify only those patients with the 358 
highest VTE risk in order to optimize patient care. To accomplish this, a score with a high 359 
sensitivity and high specificity is desirable, in which case we would only treat those patients 360 
at high risk without giving treatment to patients who will not develop VT. The L-TRiP(ascopy) 361 
score can have a high sensitivity, for example, a cut off score of 7 or higher results in a 362 
sensitivity of 77.8%. However, the corresponding specificity is only 40.2%, which implies that 363 
many controls would also receive treatment, leading to unnecessary bleeding events and 364 
costs. Determining the right cut-off for risk discrimination is therefore not straightforward, 365 
especially because of the uncertainty in the specificity of our score, which is only based on 366 
26 controls. Ideally, the absolute risks corresponding with our L-TRiP(ascopy) score should 367 
be calculated in a large prospective study so that the optimal cut-off can be determined.  368 
 369 
Conclusion 370 
Given the lack of effectiveness of thromboprophylactic therapy in all patients who undergo 371 
knee arthroscopy, an alternative strategy might be to identify those individuals at high risk 372 
of developing VT and provide stronger treatment for this group. We developed the L-373 
TRiP(ascopy) score that may be suitable for this purpose. However, a larger validation study 374 
is needed to confirm our results and to determine a definite cut-off for high risk patients.375 
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Table 1 Candidate predictor variables       
        
Environmental predictor variables       
Age Hospital admission within the past 3 months 
Sex Bedridden within the past 3 months 
 Smoking Paralysis (partial) 
  Varicose veins Surgery within the past 3 months 
 Cancer within the past 5 years Current Pregnancy or puerperium 
 Congestive heart failure Current use of antipsychotic medication 
 Comorbidity Current use of tamoxifen 
  -       Rheumatoid arthritis Current use of hormonal replacement therapy 
-       Chronic kidney disease Current use of oral contraceptives 
 -       Chronic Obstructive Pulmonary Disease (COPD) Thrombophlebitis 
  -       Multiple Sclerosis (MS) Hepatitis 
  Cardiovascular events Pneumonia 
  -       Angina Pectoris (AP) Inflammation 
  -       Heart attack -       Urinary tract infection / Cystitis 
 Cerebrovascular events -       Pyelonephritis 
  -       Stroke -       Arthritis 
  -       Transient Ischemic Attack (TIA) -       Bursitis 
  Body Mass Index (BMI) -       Inflammation (other body parts) 
 Claudication -       Tropical diseases 
  Family history of VT  (Type of) Arthroscopy 
          
Hemorheologic and coagulation predictor 
variables       
Fibrinogen activity Percentage/number granulocytes 
 Factor VIII activity Red Blood Cell Count (RBCC) 
 Von Willebrand Factor (vWF) (%) Haemoglobin level 
  Factor II activity Mean Cell Volume (MCV) 
  Factor VII activity Mean Cell Haemoglobin (MCH)
 Factor X antigen level Mean Cell Haemoglobin Concentration (MCHC) 
Protein C activity Red cell Distribution With (RDW) 
 Factor XI activity Antithrombin activity 
  Haematocrit Total homocysteine 
  White Blood Cell Count (WBCC) Total cysteine 
  Percentage/number lymphocytes Methionine 
  Percentage/number monocytes 
   
 
 
  Genetic predictor variables       
Factor V Leiden mutation  
   Prothrombin mutation  






Table 2 AUC values of the Complete, Screening, Clinical model and L-TRiP(ascopy) score in the MEGA and VTE study 
                      
    MEGA study   Internal validation 
External validation: VTE 
study 
MODEL   AUC 95% CI AUC 95% CI AUC 95% CI 
Complete model   0.81 0.70 0.93 0.78 0.67 0.89 0.75 0.42 1.00 
Screening model   0.76 0.64 0.88 0.71 0.59 0.83 0.73 0.40 1.00 
Clinical model   0.72 0.60 0.83 0.64 0.53 0.76 0.78 0.48 1.00 




 Table 3 L-TRiP(ascopy) score       
          
Risk Score Points   
Original 
Beta 
Age >= 35 and <55  2 
 
0.78 
Age >55  3 
 
1.48 
Male sex 1 
 
0.39 
Current use of oral contraceptives 3 
 
1.43 
Family history of VT (1 family member) 2 
 
0.82 
Family history of VT (>=2 family members) 3 
 
1.47 
Bedridden within the past 3 months 3 
 
1.38 
Varicose Veins 1 
 
0.68 
Congestive heart failure 1 
 
0.49 
Knee arthroscopy  4 
 
1.76 
  Ligament reconstruction 6 
 
2.93 
This score was derived from the regression coefficients (Beta) of the Clinical 
  prediction Model. Beta>0.25 and ≤0.75=1; Beta>0.75 and ≤1.25=2; Beta>1.25  
  and ≤1.75=3; Beta>1.75 and ≤2.25=4; Beta>2.25 and ≤2.75=5; Beta>2.75=6 





Table 4 L-TRiP(ascopy) score performance        
                    
Cutpoint Sensitivity Specificity Sens+Spec PVV* NPV* PVV** NPV** Likelihood+ Likelihood- 
                    
1 100.0% 0.0% 100.0% 1.50% 100.0% 0.50% 100.0% 1.0 0.0 
2 100.0% 0.0% 100.0% 1.50% 100.0% 0.50% 100.0% 1.0 0.0 
3 100.0% 0.0% 100.0% 1.50% 100.0% 0.50% 100.0% 1.0 0.0 
4 100.0% 0.0% 100.0% 1.50% 100.0% 0.50% 100.0% 1.0 0.0 
5 100.0% 0.0% 100.0% 1.50% 100.0% 0.50% 100.0% 1.0 0.0 
6 92.3% 21.7% 114.1% 1.77% 99.5% 0.59% 99.8% 1.2 0.2 
7 77.8% 40.2% 117.9% 1.94% 99.2% 0.65% 99.7% 1.5 0.2 
8 68.8% 64.4% 133.2% 2.86% 99.3% 0.96% 99.8% 1.5 0.4 
9 43.2% 84.9% 128.1% 4.17% 99.0% 1.42% 99.7% 1.8 0.4 
10 29.0% 99.1% 128.0% 32.15% 98.9% 13.52% 99.6% 3.1 0.6 
11 17.9% 100.0% 117.9% 100.00% 98.8% 100.00% 99.6% 29.9 0.6 
12 7.1% 100.0% 107.1% 100.00% 98.6% 100.00% 99.5% 21.7 0.7 
13 3.6% 100.0% 103.6% 100.00% 98.6% 100.00% 99.5% ∞ 0.9 
14 1.9% 100.0% 101.9% 100.00% 98.5% 100.00% 99.5% ∞ 0.9 
*Presuming a prevalence of VT in knee arthroscopy patients of 1.5%         










Figure 2: AUC values of the Complete model for step-wise addition of the following predictors: age, 466 
sex, von Willebrand Factor activity, family history of VT, Factor V Leiden mutation, being bedridden 467 
within the past 3 months, current use of oral contraceptives, (type) of knee arthroscopy, Factor VIII 468 




Figure 3: Risk score distribution among cases and controls for the L-TRiP(ascopy)score (upper figure) 473 
and Screening model (lower figure). Dashed black lines represent Cut-off values that correspond to a 474 
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